Seeking Alpha

Isis Pharmaceuticals (ISIS -5.5%) says it's earned a $10M milestone payment from AstraZeneca's...

Isis Pharmaceuticals (ISIS -5.5%) says it's earned a $10M milestone payment from AstraZeneca's (AZN) decision to add a second development candidate to their collaboration on cancer antisense drugs. ISIS had struck the deal in December to develop therapeutics against five cancer targets, including an exclusive license for AZN to develop ISIS-STAT3, a drug ISIS was evaluating for treating advanced lymphoma. It's now adding a second development candidate, ISIS-AR(Rx), to the collaboration.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs